GlaxoSmithKline Pakistan Limited Sustainability Profile
GlaxoSmithKline Pakistan Limited, commonly referred to as GSK Pakistan, is a leading healthcare company headquartered in Karachi, Pakistan. Established in 1947, GSK Pakistan has made significant strides in the pharmaceutical and consumer healthcare sectors, focusing on innovative medicines, vaccines, and consumer health products. With a strong presence across major regions in Pakistan, GSK Pakistan is renowned for its commitment to improving health outcomes through its diverse portfolio, which includes prescription medications, over-the-counter products, and vaccines. The company is particularly noted for its advancements in respiratory and infectious disease treatments. As a subsidiary of GlaxoSmithKline plc, GSK Pakistan has achieved notable market recognition, consistently ranking among the top pharmaceutical companies in the country, driven by its dedication to research and development and a robust distribution network.
DitchCarbon Score
How does GlaxoSmithKline Pakistan Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline Pakistan Limited's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline Pakistan Limited, headquartered in PK, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of GSK plc, which influences its climate commitments and initiatives. GSK plc has set ambitious climate targets, including commitments to reduce emissions across its operations. These targets are cascaded to GlaxoSmithKline Pakistan Limited, aligning with the Science Based Targets initiative (SBTi) and other sustainability frameworks. The company is actively involved in initiatives such as RE100, which aims for 100% renewable electricity, and the Climate Pledge, which focuses on achieving net-zero emissions. While specific reduction targets for GlaxoSmithKline Pakistan Limited are not detailed, the overarching goals from GSK plc indicate a strong commitment to sustainability and reducing carbon footprints across its global operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,040,928,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 788,149,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,630,521,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is GlaxoSmithKline Pakistan Limited's Industry?
How Carbon Intensive is GlaxoSmithKline Pakistan Limited's Location?
GlaxoSmithKline Pakistan Limited's Scope 3 Categories Breakdown
GlaxoSmithKline Pakistan Limited's Scope 3 emissions, which decreased by 0% last year and decreased by approximately 46% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
GlaxoSmithKline Pakistan Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GlaxoSmithKline Pakistan Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
